NASDAQ
COLL
Last Price
US $35.02
KEY FIGURES
MKT CAP
$1.1B
EPS
TTM
$2.34
PEG
TTM
N/M
P/E
TTM
14.99x
P/S
TTM
1.41x
YIELD
0.00%
GROWTH
Revenue Y/Y
20.28%
(FY vs FY)
EBITDA Y/Y
Cash Flow (DCF)
Fair Value
Market $35.02
—
Default assumptions
EBITDA Multiple
Fair Value
Market $35.02
90.43%
Default assumptions
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Collegium Pharmaceutical, Inc. cash flow to debt ratio of 35.01% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.
Financial stability - Healthy cash flow growth.
Collegium Pharmaceutical, Inc.'s free cash flow has increased 61.11% from $203.33M last year to $327.58M, signaling increasing performance
Financial risk - Healthy debt to equity ratio.
Collegium Pharmaceutical, Inc.'s debt to equity ratio is 2.59, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial stability - Healthy debt to equity ratio development.
Collegium Pharmaceutical, Inc.'s debt has decreased relative to shareholder equity from 3.75 last year to 2.59 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Collegium Pharmaceutical, Inc. has a net debt to EBITDA ratio of 1.72x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial risk - ICR.
Collegium Pharmaceutical, Inc.'s interest coverage ratio is 1.17, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial risk - Profit margin growth.
Collegium Pharmaceutical, Inc.'s profit margin has decreased (-14.11%) in the last year from 10.96% to 9.41%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
Collegium Pharmaceutical, Inc.'s short-term assets of $691.41M exceed its short-term liabilities of $440.03M
Decreasing performance - ROA.
Collegium Pharmaceutical, Inc.'s return on assets of 4.54% is lower than the 5.00% threshold, indicating inefficient asset utilization
Increasing performance - Absolute return on equity.
Collegium Pharmaceutical, Inc.'s return on equity of 26.74%, is higher than 15.00%, indicating good performance
Increasing performance - Earnings quality.
Collegium Pharmaceutical, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Increasing performance - Earnings stability.
Collegium Pharmaceutical, Inc. had positive net income in 4.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
Collegium Pharmaceutical, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Collegium Pharmaceutical, Inc. has a free cash flow yield of 28.84%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Decreasing performance - Healthy earnings growth.
Collegium Pharmaceutical, Inc.'s yearly earnings has decreased -9.13% since last year from $69.19M to $62.87M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
Collegium Pharmaceutical, Inc.'s yearly revenue has increased 23.62% since last year from $631.45M to $780.57M, signaling increasing performance
Increasing performance - ROIC.
ROIC 10.51% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Increasing performance - 3-year revenue CAGR.
Collegium Pharmaceutical, Inc.'s 3-year revenue CAGR of 18.94% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Collegium Pharmaceutical, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
Collegium Pharmaceutical, Inc. had positive ROE in 4.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Collegium Pharmaceutical, Inc. has insufficient data to evaluate this check.
Undervalued - Earnings yield.
Collegium Pharmaceutical, Inc. has an earnings yield of 6.67%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Undervalued - EBITDA valuation.
Collegium Pharmaceutical, Inc. is undervalued relative to its fair value price of 66.69 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Collegium Pharmaceutical, Inc. has an EV/EBITDA ratio of 4.55x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Undervalued - PEG ratio value.
Collegium Pharmaceutical, Inc. has a PEG-ratio under 1 which is considered undervalued
Undervalued - P/B ratio.
Collegium Pharmaceutical, Inc. has a price-to-book ratio of 3.60x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Collegium Pharmaceutical, Inc. has a price-to-sales ratio of 1.41x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
26.74%
Return on equity
ROIC: 10.51%
Valuation History
14.9X
Price to Earnings
EV/EBITDA: 2.8X
Cash flow
Profit margin
27.72%
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
EARNINGS FV (GRAHAM)
Fair Value
Market $35.02
177.24%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.